Jasper Therapeutics's total revenue is $0, below the sector sector average of $1.2B.
Get informed when a big investor buys or sells
+ FollowAs of Mar 2026
Trailing 12 months ending Mar 2026
Jasper Therapeutics (JSPR) currently reports a total revenue of $0 as of March 2026. That compares with $1.2M in the prior-year period — down 100.0% year over year. That is below the sector sector average of $1.2B. Use the charts on this page to explore Jasper Therapeutics's total revenue history and peer comparisons.
Jasper Therapeutics's total revenue decreased from $1.2M to $0 — a 100.0% year-over-year decrease (period ending March 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.
Jasper Therapeutics's total revenue of $0 is lower than the its sector sector average of $1.2B. That is roughly 100.0% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.
Jasper Therapeutics reported $0 in total revenue as of March 2026. That compares with $1.2M in the prior-year period — down 100.0% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.
Start with the current total revenue of $0, then check the historical chart for trend and the peer comparison chart for relative positioning. The sector average is $1.2B. From there, open related valuation or income-statement pages for Jasper Therapeutics, and consider following JSPR for alerts when major investors trade the stock.